Cite
HARVARD Citation
Lowe, J. et al. (2016). Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. Journal for immunotherapy of cancer. 4 (1), p. . [Online].